Get the Stockscreener App
256.55
2.00%
5.04
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $256.55, with a volume of 704.06K.
It is up +2.00% in the last 24 hours and up +4.62% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$251.51
Open:
$255
24h Volume:
704.06K
Relative Volume:
0.69
Market Cap:
$37.45B
Revenue:
$5.26B
Net Income/Loss:
$1.44B
P/E Ratio:
26.26
EPS:
9.7713
Net Cash Flow:
$1.76B
1W Performance:
+0.28%
1M Performance:
+4.62%
6M Performance:
+2.75%
1Y Performance:
+7.16%
1-Day Range:
$254.40
$257.98
1-Week Range:
$237.62
$257.98
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
256.55 | 36.71B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
575.34 | 201.58B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
193.96 | 55.30B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.73 | 38.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
WST
West Pharmaceutical Services Inc
|
280.23 | 20.27B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Is It Too Late To Consider ResMed After Obesity and Sleep Apnea Headlines? - Yahoo Finance
Peter Farrell Sells 2,000 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Invesco Ltd. Has $563.42 Million Holdings in ResMed Inc. $RMD - MarketBeat
How ResMed Inc. (Common Stock) (RMEA) stock reacts to fiscal policies2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - Newser
Is ResMed Inc. (Common Stock) (RMEA) stock inflation resilient2025 Momentum Check & Real-Time Market Trend Scan - Newser
Baird Financial Group Inc. Has $51.44 Million Holdings in ResMed Inc. $RMD - MarketBeat
1832 Asset Management L.P. Grows Position in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock deliver stable dividends2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Does ResMed Inc. stock trade below intrinsic valueQuarterly Trade Review & Safe Entry Point Identification - Newser
Is ResMed Inc. stock among top earnings plays2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - Newser
Is ResMed Inc. (Common Stock) (RMEA) stock nearing a technical breakoutRate Hike & Daily Growth Stock Investment Tips - Newser
ResMed Inc Announces Changes in Beneficial Ownership - TipRanks
ResMed Inc Announces Proposed Sale of Securities by Director - TipRanks
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Will ResMed Inc. (Common Stock) (RMEA) stock see valuation expansion2025 Top Decliners & Risk Controlled Daily Plans - Newser
Can ResMed Inc. (Common Stock) (RMEA) stock beat analyst consensusTrade Entry Summary & Reliable Trade Execution Plans - Newser
Is ResMed Inc. stock vulnerable to rate hikesJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
ResMed director Farrell sells $502k in stock By Investing.com - Investing.com South Africa
Will ResMed Inc. stock beat revenue estimatesLayoff News & Daily Growth Stock Investment Tips - Newser
ResMed director Farrell sells $502k in stock - Investing.com
Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing - marketscreener.com
How strong dollar benefits ResMed Inc. (Common Stock) (RMEA) stockTrade Signal Summary & Expert Approved Momentum Ideas - Newser
What makes ResMed Inc. stock appealing to growth investors2025 Short Interest & Risk Adjusted Swing Trade Ideas - Newser
Will ResMed Inc. stock benefit from mergersGap Down & Reliable Price Breakout Signals - Newser
ResMed Inc Reports Changes in CHESS Depositary Interests and Securities - MSN
Is ResMed Inc. (Common Stock) (RMEA) stock in buy zone after pullbackQuarterly Growth Report & Community Driven Trade Alerts - Newser
How ResMed Inc. (Common Stock) (RMEA) stock trades after earningsM&A Rumor & Real-Time Sentiment Analysis - Newser
Is ResMed Inc. (RME) stock worth buying before Fed actionJuly 2025 Trends & Stepwise Trade Signal Guides - Newser
How dovish Fed policy supports ResMed Inc. stockJuly 2025 Reactions & Low Risk Entry Point Guides - Newser
Is ResMed Inc. stock supported by free cash flow2025 Volatility Report & Weekly High Momentum Picks - Newser
Quantbot Technologies LP Purchases 25,810 Shares of ResMed Inc. $RMD - MarketBeat
Should You Continue to Hold RMD Stock in Your Portfolio? - TradingView
Schroder Investment Management Group Has $37.78 Million Stock Position in ResMed Inc. $RMD - MarketBeat
Should Goldman’s Conviction List Exit and New Stock Plans Require Action From ResMed (RMD) Investors? - simplywall.st
How ResMed Inc. stock compares with market leadersJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Why ResMed Inc. stock benefits from AI revolutionJuly 2025 Rallies & Detailed Earnings Play Strategies - Newser
Resmed CFO Sandercock sells $244,160 in stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
ResMed Officer Plans Further Share Sale Under Rule 144 - TipRanks
Resmed CFO Sandercock sells $244,160 in stock - Investing.com
1,187,798 Shares in ResMed Inc. $RMD Acquired by Norges Bank - MarketBeat
Scotia Capital Inc. Has $2.11 Million Position in ResMed Inc. $RMD - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):